Clinical Trial Update: A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain [Phase 3]

View source ↗

Summary

This clinical trial update reports the termination of a Phase 3 study evaluating intravenous/oral ibandronate (Bondronat) for metastatic bone disease with pain.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastasis

Drugs mentioned

• Bondronat (ibandronic acid)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Pain, Bone Neoplasm | Phase 3 | Status: TERMINATED